Goldline Pharmaceutical was incorporated on August 02, 2004. The company markets pharmaceutical products under the “Goldline” brand across five segments, including pharma, wellness, and ayurvedic categories. Its products are manufactured through third-party partners based on the company’s specifications, market research, and quality standards
| Bidding Dates |
|---|
| 12 May 2026 - 14 May 2026 |
| Subscription |
|---|
| 781.85x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,46,000 | 2 | 2 | 3000 | 2.7 M | ₹41 - ₹43 | 57.29 % | ₹110.7 M - ₹116.1 M | RHP DOC |
Goldline Pharmaceutical IPO SUBSCRIPTION STATUS
14 May '26Goldline Pharmaceutical IPO overall subscription rate was 781.85 times the total available shares
Goldline Pharmaceutical IPO retail subscription rate was 1151.33 times in the retail segment
Goldline Pharmaceutical IPO non-institutional investor subscription rate was 2196.25 times in the non-institutional investor category
Goldline Pharmaceutical IPO Qualified Institutional Bidder subscription rate was 98.9 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
14 May 2026 (Day 3) | 1151.33x | 2196.25x | 98.9x |
13 May 2026 (Day 2) | 182.29x | 193.52x | 0.72x |
12 May 2026 (Day 1) | 44.51x | 32.32x | 0.72x |
Goldline Pharmaceutical FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 9MFY26 | 21.4 | 2.2 | 2.3 | 2.3 | 19.4% |
| FY25 | 28.1 | 2.8 | 2.3 | 2.5 | 20.8% |
| FY24 | 23.6 | 1.8 | 2.9 | 1.8 | 18.3% |
| FY23 | 19.8 | 0.3 | 2.4 | 1.4 | 11.1% |
Goldline Pharmaceutical IPO SUBSCRIPTION STATUS DETAILS
Goldline Pharmaceutical had 2.7 M shares on offer
Goldline Pharmaceutical IPO offer price was in the range ₹41 - ₹43
Goldline Pharmaceutical IPO minimum Investment was ₹246000
Goldline Pharmaceutical IPO issue size was ₹ 110.7 M - ₹ 116.1 M
Goldline Pharmaceutical had a minimum lot size of 3000 Shares per application
Goldline Pharmaceutical NUMBER OF SHARES ON OFFER
Goldline Pharmaceutical IPO IMPORTANT DATES
| Issue Open Date | 12 May 2026 |
| Issue close Date | 14 May 2026 |
| Allotment Date | 15 May 2026 |
| Refund Date | 18 May 2026 |
| Demat Account Credit Date | 18 May 2026 |
| Listing Date | 19 May 2026 |
| Listing on Exchange(s) | BSE |
| Goldline Pharmaceutical Allotment Status | Exchange/ Registrar |
Goldline Pharmaceutical IPO subscription opened on 12 May 2026, and closed on 14 May 2026
IPO allotment for Goldline Pharmaceutical was finalized on Friday, 15 May 2026
IPO listing for Goldline Pharmaceutical was on BSE on Tuesday, 19 May 2026
Goldline Pharmaceutical IPO LISTING GAINS
| Issue Price (adjusted) | 43.0 |
| Listing Open Price | 59.8 |
| Listing Close Price | 56.8 |
| Listing Gain% | 39.0% |
| Current Gain% | -2.3% |
Goldline Pharmaceutical Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Ltd. | 42 | 40.3 | 9.8 | 0.2 | 1.3 | 33.1 | 14.3 | 31.2 | 11.2 | 4.1 | 45.4 | 4.3 | 45.4 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Goldline Pharmaceutical INFORMATION ON IPO ISSUE
About Goldline Pharmaceutical
Goldline Pharmaceutical was incorporated on August 02, 2004. The company markets pharmaceutical products under the “Goldline” brand across five segments, including pharma, wellness, and ayurvedic categories. Its products are manufactured through third-party partners based on the company’s specifications, market research, and quality standards
Object of the Issue
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by the company
- General corporate purposes
Goldline Pharmaceutical - PROMOTERS
| Name |
|---|
| Amol Laxmikant Mujumdar |
| Swapan Premprakash Khandelwal |
Goldline Pharmaceutical - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Amol Laxmikant Mujumdar | Chairman & Managing Director |
| Swapan Premprakash Khandelwal | Whole-Time Director |
| Prashant Shrikrishna Karkare | Executive Director |
| Avinash Pandurang Ambulkar | Executive Director |
| Prashant Vithalrao Rahate | Non-Executive Director |
| Mehul Hari Ranade | Independent Director |
| Renuka Saurabh Borole | Independent Director |
| Shraddha Kiran Kulkarni | Independent Director |
Goldline Pharmaceutical Book Running Lead Manager
Cumulative Capital Private Limited
contact@cumulativecapital.group
Goldline Pharmaceutical Registrar to the issue
Bigshare Services Private Limited
ipo@bigshareonline.com
Goldline Pharmaceutical Strengths
Asset-light business model
The company follows an asset-light business model by sourcing products through manufacturing partners instead of investing in its own production facilities. This approach enhances capital efficiency, supports scalable growth, improves cash flow management, and reduces operational risk
Diverse product range
The company offers a diversified portfolio across the Goldline Pharma, Cardinal, Aayushman, InLife, and Wellness segments, with products manufactured through contract manufacturing based on market demand and customer requirements. Its established network and industry experience support the introduction of new products and portfolio expansion
Vendor relationship
The company has built long-term relationships with suppliers and vendors, ensuring a stable supply of raw materials and uninterrupted operations. These partnerships also support favorable pricing and supply terms, helping reduce operational risks
Goldline Pharmaceutical Risks
Working capital intensive
The company’s operations require substantial working capital, primarily for inventory and trade receivables, making efficient cash flow management critical. Any inability to secure sufficient funding or delays in customer payments could adversely impact its operations and financial performance
Operational risks
The company relies heavily on its IT systems to manage supply chain, procurement, logistics, accounting, and distribution operations. Any system failure, cyber risk, or prolonged disruption could interrupt business operations, expose sensitive data, and adversely affect its financial performance and reputation
Patent infringement litigation risk
The company operates in an industry prone to patent-related disputes, and any inadvertent infringement of third-party patents could lead to litigation, financial liabilities, or restrictions on product sales. Such outcomes may adversely affect its business operations, financial condition, and future growth
IPO FAQs
The promoters of the company are Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 41.0 - 43.0.
The IPO application opens on May 12, 2026 and closes on May 14, 2026.
The minimum lot size for the IPO is 6000. The maximum lot size for the IPO is 6000.
For all category investors, the minimum application amount for this IPO is Rs. 246,000.0, the maximum value for this IPO is Rs 258,000.0.
This IPO will be allotted on May 15, 2026.
The refund will be credited to your account on May 18, 2026.
The allotted shares will be credited to your demat on May 18, 2026.
Goldline Pharmaceutical Ltd.’s shares listed on the stock exchanges on May 19, 2026.